Algeta signs technology access deal with Lumiphore
This article was originally published in Scrip
Executive Summary
Algeta has acquired an exclusive 12-month option to license Lumiphore's Lumi4 chelator technology within the field of therapeutic radiopharmaceuticals. The Norwegian oncology-focused company hopes to evaluate the Lumi4 technology for its ability to bind the alpha-emitter thorium-227 and link it to tumour-targeting molecules, such as antibodies. Algeta said that the benefits of licensing Lumiphore's technology could include more rapid, efficient and cost-effective chelation and conjugation processes for its radionuclide-based therapeutics, and increased conjugate stability.